Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
16 December 2017 |
Main ID: |
NCT03090035 |
Date of registration:
|
27/02/2017 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment
|
Scientific title:
|
Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses in Chronic Hepatitis C Treatment |
Date of first enrolment:
|
January 1, 2014 |
Target sample size:
|
98 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT03090035 |
Study type:
|
Interventional |
Study design:
|
Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
Pakistan
| | | | | | | |
Contacts
|
Name:
|
Muhammad ZM Babar, FCPS |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Sheikh Zayed Medical College/Hospital |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- patients with diagnosis of chronic hepatitis C genotype 2 or 3
Exclusion Criteria:
- Patients with hepatitis genotype I and IV
Age minimum:
20 Years
Age maximum:
80 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Hepatitis C Relapse
|
Hepatitis C
|
Intervention(s)
|
Drug: Ribavirin
|
Drug: Pegylated Interferon a2
|
Primary Outcome(s)
|
Treatment Success rate
[Time Frame: after 24 weeks of treatment]
|
Secondary Outcome(s)
|
Relapse Rate
[Time Frame: After 48 weeks of treament]
|
Sustained Virological Response
[Time Frame: After 48 weeks of treament]
|
Secondary ID(s)
|
sheikhZMC
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|